

**To:** 5.1.2e [ 5.1.2e @rivm.nl]; 5.1.2e @radboudumc.nl [ 5.1.2e @radboudumc.nl]  
**Cc:** 5.1.2e [ 5.1.2e @rivm.nl]  
**From:** 5.1.2e  
**Sent:** Mon 11/2/2020 8:49:13 AM  
**Subject:** RE: case control study community risk  
**Received:** Mon 11/2/2020 8:49:15 AM  
[20200722 COVID-19 riskfactors researchproject protocol DRAFT 1.7.docx](#)  
[20200910 COVID-19 risicofactoren teststraten vragenlijst CONCEPT 1.17.docx](#)

Hi 5.1.2e

Please find attached the latest version of the protocol and questionnaire. 5.1.2i Wetenschappelijk beraad  
 5.1.2i Wetenschappelijk beraad

That does sound very interesting to do a case-control study among HCW. It would be great to hear how it goes.

Best wishes,

5.1.2e

---

**From:** 5.1.2e < 5.1.2e @rivm.nl >  
**Sent:** 02 November 2020 09:35  
**To:** 5.1.2e @radboudumc.nl' < 5.1.2e @radboudumc.nl >; 5.1.2e < 5.1.2e @rivm.nl >  
**Cc:** 5.1.2e < 5.1.2e @rivm.nl >  
**Subject:** RE: case control study community risk

Hi 5.1.2e

Very interesting that you start a case control study in HCWs.

5.1.2e can share the latest version of our protocol and questionnaire. 5.1.2i Wetenschappelijk beraad

5.1.2i Wetenschappelijk beraad Unfortunately our study has not started yet due to all regulations around privacy. As in principle all people going to the teststraat could potentially participate in the study, we wanted to arrange this in a good way and especially after the dataleak with Infectieradar, and this takes time...

Here also an interesting paper from Jan Vandenbroucke on (test-negative) case control studies for COVID:

[https://journals.lww.com/epidem/Fulltext/2020/11000/A\\_Test\\_Negative\\_Design\\_with\\_Additional\\_Population.12.aspx](https://journals.lww.com/epidem/Fulltext/2020/11000/A_Test_Negative_Design_with_Additional_Population.12.aspx)  
 X

Good luck with setting up the study. Let me know if you have any questions or want to discuss.

All the best,

5.1.2e

---

**From:** 5.1.2e @radboudumc.nl < 5.1.2e @radboudumc.nl >  
**Sent:** zondag 1 november 2020 15:34  
**To:** 5.1.2e < 5.1.2e @rivm.nl >; 5.1.2e < 5.1.2e @rivm.nl >  
**Cc:** 5.1.2e < 5.1.2e @rivm.nl >  
**Subject:** case control study community risk

Dear 5.1.2e

I found out via 5.1.2e that you are working on a case control study on community (and household?) risk factors for COVID infection. Very interesting. I also understood this has been ready to go since May? To my surprise there have not been that many CC-studies on community risk factors, which would have been very helpful. But anyway.

I am starting a cc-study in our hospital because we get many COVID+ HCWs with an unknown likely source of infection and we want to get a grip on this. We have targeted some risk situations in the hospital by refining our in-hospital protocols (e.g. targeting coffee/lunch breaks). We wanted to start a case-control study to get some additional insight in risk factors for exposure.

This is the only reported study I could find on this topic:

[https://www.cdc.gov/mmwr/volumes/69/wr/mm6936a5.htm?s\\_cid=mm6936a5\\_w](https://www.cdc.gov/mmwr/volumes/69/wr/mm6936a5.htm?s_cid=mm6936a5_w)

I wanted to ask you: would you be able to share your protocol and/or questionnaire with me to get some inspiration, and to align some of the questions with yours so that findings may be comparable where possible. So, has the cc-study already started? Do you have some preliminary findings (that you can share)?

In general, we want to ask about household situation (e.g. how many children/ what age), social / leisure activities (following the obvious risk factors on a generic level), and some obvious in-hospital factors. The questionnaire will be anonymous

We should have started this earlier – because our positivity rates start to decline (which is good news). We want to go back in time a little bit, but I am afraid we cannot go back too far. How many weeks would you recommend? I hope to be able to start within 2 weeks.

Many thanks & greetings from Nijmegen.

Met vriendelijke groet,

5.1.2e

5.1.2e

5.1.2e

Afdeling Medische Microbiologie

E: 5.1.2e@radboudumc.nl

T: 024 5.1.2e (secre) 5.1.2e direct | 06 5.1.2e

**Radboud Centrum voor Infectieziekten**

Postbus 9101, 6500 HB Nijmegen

Geert Grooteplein Zuid 22 (route & huispost 5.1.2e)

[www.radboudumc.nl](http://www.radboudumc.nl)

*De informatie in dit bericht is uitsluitend bestemd voor de geadresseerde. Aan dit bericht en de bijlagen kunnen geen rechten worden ontleend. Heeft u deze e-mail onbedoeld ontvangen? Dan verzoeken wij u het te vernietigen en de afzender te informeren. Openbaar maken, kopiëren en verspreiden van deze e-mail of informatie uit deze e-mail is alleen toegestaan met voorafgaande schriftelijke toestemming van de afzender. Het Radboudumc staat geregistreerd bij de Kamer van Koophandel in het handelsregister onder nummer 41055629.*

*The content of this message is intended solely for the addressee. No rights can be derived from this message or its attachments. If you are not the intended recipient, we kindly request you to delete the message and inform the sender. It is strictly prohibited to disclose, copy or distribute this email or the information inside it, without a written consent from the sender. Radboud university medical center is registered with the Dutch Chamber of Commerce trade register with number 41055629.*